Chemogenetic ON and OFF switches for RNA virus replicationEmmanuel Heilmann, Dorotheé von Laer, Janine Kimpel et al.|Nature Communications|2021Cited by 12
Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotypeZoltán Bánki, Guido Wollmann, Knut Elbers et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 9
2284P Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)A. Ackermann, Jörg F. Rippmann, Patrik Erlmann et al.|Annals of Oncology|2023Cited by 0
An ex vivo permissivity assay to assess replication of the oncolytic virus VSV-GP in patient-derived tumor samplesBenjamin Schoeps, Krishna Das, Stefanie Estermann et al.|Oncogene|2026Cited by 0
Oncolytic virus-delivered GSDME: Unlocking pyroptosis to improve dendritic cell function and amplify cytotoxic T cell responseSabrina Schneider, Tobias Nolden, Theresa Schwaiger et al.|Molecular Therapy Oncology|2026Cited by 0